BACKGROUND Follicular lymphoma is an indolent non-Hodgkin lymphoma that is most commonly diagnosed in elderly individuals. The majority of patients with follicular lymphoma present with advanced disease. Despite the recent advances in treatment, there remains a substantial unmet need for effective treatments for patients with relapsed/refractory follicular lymphoma. The PI3Kδ inhibitor idelalisib was approved by the European Medicines Agency in 2014 as a monotherapy for the treatment of adult patients with follicular lymphoma that is refractory to two prior lines of treatment. Real-world evidence from patients with follicular lymphoma treated with idelalisib indicates its utility in these patients. CASE PRESENTATION This case report describes an 82-year-old, retired, white, female patient with refractory follicular lymphoma who achieved a partial response with idelalisib treatment. Despite experiencing two incidences of a psoriasis-like rash during idelalisib treatment that required effective management with topical steroids, the patient was able to restart treatment successfully and maintain a continued partial response. CONCLUSIONS The clinical relevance of the effective management of adverse events in this case demonstrates the opportunity to enable patients to remain on therapy, thereby maintaining long-term response and improving overall outcomes.

中文翻译：

---

难治性滤泡性淋巴瘤患者与依达拉西单药治疗相关的牛皮癣样皮疹的治疗。

背景技术滤泡性淋巴瘤是一种惰性的非霍奇金淋巴瘤，最常在老年患者中诊断。大多数滤泡性淋巴瘤患者均患有晚期疾病。尽管最近在治疗方面取得了进展，但是对于复发/难治性滤泡性淋巴瘤患者仍然没有有效治疗的需求。PI3Kδ抑制剂艾达拉西布在2014年被欧洲药品管理局（European Medicines Agency）批准为单一药疗法，用于治疗对先前两种治疗方法均无效的成人滤泡性淋巴瘤患者。依德利西布治疗的滤泡性淋巴瘤患者的真实证据表明其在这些患者中的效用。病例介绍该病例报告描述了一位82岁，退休，白人，难治性滤泡性淋巴瘤的女性患者，使用艾得拉西布治疗可部分缓解。尽管在艾屈拉西布治疗期间发生两次牛皮癣样皮疹的发生，需要使用局部类固醇进行有效治疗，但患者仍能够成功地重新开始治疗并维持持续的部分缓解。结论在这种情况下，有效管理不良事件的临床意义证明了有机会使患者继续接受治疗，从而保持长期反应并改善总体疗效。患者能够成功地重新开始治疗并保持持续的部分反应。结论在这种情况下，有效管理不良事件的临床意义证明了有机会使患者继续接受治疗，从而保持长期反应并改善总体疗效。患者能够成功地重新开始治疗并保持持续的部分反应。结论在这种情况下，有效管理不良事件的临床意义证明了有机会使患者继续接受治疗，从而保持长期反应并改善总体疗效。